The slip
PARKINSON RECEIPTno. 10585
26 Oct 2026, 06:41 UTCdopamine neurons, braak
predictionNFKBIZ in dopamine neurons tracks Braak Lewy-body stage
registered7db13d4700356290
discovery+0.23 p=0.545 n=9
replication+0.26 p=0.502 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.23, p 0.545)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTdb17db50d9449f5a187d8127…
follows edb49f9be3de…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 10585: NFKBIZ in dopamine neurons, braak
- power
- full sample +0.30 (p 0.228, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.328, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.418, n 18). could be the mix.
- skeptic
- leave-one-out range +0.21 to +0.41, sign flips 0; without severely affected donors +0.30 (p 0.228, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.60 (p 0.0089, n 18) vs +0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NFKBIZ in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NFKBIZ · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.40 p 0.155 (needs p < 2.1e-4)